Friday, February 27, 2015
Thursday, February 26, 2015
This article, Acorda 2015: Patents, Pipeline and Patients; Cash and Catalysts is a Pro article and will be available to non-Pro parties until March 23. The article focuses on 2015 and does not include longer term potential (phase I initiatives, for example). The recent drop in price on Acorda may have to do with Kyle Bass' recent patent challenge (inter partes review) and/or the corresponding short selling that is presumed to have taken place/is taking place.